Modern medicine depends on large, information-rich molecules such as peptides and oligonucleotides. These molecules carry biological instructions that can be directed toward specific disease pathways.
As more experimental DNA drugs move through the clinic and into large-scale trials, the demand for efficient and cost-effective manufacturing strategies is intensifying. Higher yields, greater purity, ...
Market research figures compiled by Agilent Technologies reveal that in 2009, $407 million in direct financing was targeted to the development of oligonucleotide therapeutics in the U.S. This figure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results